If oil and water don’t mix then why would you mix your medications and CBD?
It always amazes me what some Doctors recommendations to their patients. Recently, had a phone call from a potential client they needed CBD as of today because their MD recommended it for sleep. I follow up with a phone call as they were in the store with a CBD product in hand, ready to purchase. I ask are you currently taking any medications. They say YES! Then I get why are you asking? The short answer is recent studies have shown that CBD inactivates cytochrome P450 isozymes in the short term. The long answer is that cannabinoids specifically CBD will inhibit the function of the P450 liver enzyme that clears toxins (medications) which in turn keeps them in your system longer which may lead to a toxic drug effects.
CBD is metabolized, among others, via the CYP3A4 enzyme. Various drugs such as ketoconazol (Antifungal), itraconazol (Antifungal), ritonavir (HIV antiviral), and clarithromycin (Antibiotics) inhibit this enzyme which leads to higher CBD doses that are longer pharmaceutically active. In contrast, phenobarbital (Barbiturate), rifampicin (Antibiotics), carbamazepine (Anticonvulsant), and phenytoin (Anticonvulsant) induce CYP3A4, causing reduced CBD bioavailability.
KNOW WHAT DRUGs YOUR PATIENTS ARE TAKING BEFORE RECOMMENDING CBD!
This may lead to other health problems developing. So, don’t just go and blindly pick something off the shelf at the store because your doctor said so. You may be setting yourself up for toxic overload. I recommended finding educated individuals or healthcare practitioner when trying to navigate using cannabinoids or nutritional products.
Also, note that CBD is fat soluble (lipophilic) which means you should take with meals so the liver can break it down with bile salts. Don’t ever take CBD with your prescriptions.
The reality is more complex. To learn more contact BagnellSolutions.com
-Dr. Lawrence Bagnell 10/03/2018
Lipophilic defined: tending to combine with or dissolve in lipids or fats.
Resourced from: Cannabis and Cannabinoid Research,Volume 2.1, 2017,DOI: 10.1089/can.2016.0034/An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies,Kerstin Iffland and Franjo Grotenhermen / CBD-drug interactions